Netflix's "Unnatural Selection" Ducks the Big Questions About Gene Editing
By Jonathan R. Latham,
Salon
| 11. 10. 2019
The opening scene of "Unnatural Selection," a four-part docuseries released recently from Netflix, depicts scientist Jennifer Doudna showing off a tiny sample of a colorless liquid. It contains, she says, an enzyme that allows her to add or remove any piece of DNA from any living organisms. This scene launches an exploration of the people who are taking up — and talking up — that opportunity, which Doudna did much to bring about. In this scene though, as in the remainder of the series, there is scant pushback on the hyperbolic narratives tracked over the four episodes. But, having built up the potential of gene editing, "Unnatural Selection" fails to explore the qualifications and correctives that call into question the whole project of gene editing. One wonders, in fact, if the filmmakers were even aware of the larger existential questions it raises.
The protagonists of the series span an extraordinarily wide spectrum. Spark Therapeutics claims to have invented a gene therapy cure for a special kind of inherited blindness. The biotech company has chosen its smooth-talking and sharply dressed company...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...